Evidence map›Paper›PMID 28430622›Full record

SynthesisOncotarget2017

Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis.

Runzhen Zhao, Zhenlei Su, Jing Wu, Hong-Long Ji

Open access · diamondAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 5 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 5 syntheses or guidelines pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Runzhen ZhaoTexas Lung Injury Institute, University of Texas Health Northeast, Tyler, Texas, USA.
Zhenlei SuInstitute of Lung and Molecular Therapy, Xinxiang Medical University, Xinxiang, Henan, China.
Jing WuInstitute of Lung and Molecular Therapy, Xinxiang Medical University, Xinxiang, Henan, China.
Hong-Long JiTexas Lung Injury Institute, University of Texas Health Northeast, Tyler, Texas, USA.
The University of Texas Health Science Center at Tyler · USXinxiang Medical University · CN

Funding

Regulation of lung epithelial sodium channels by cGMPR01HL087017 · NHLBI · UNIVERSITY OF TEXAS HLTH CTR AT TYLER · PI JI, HONG-LONG · 2007 to 2011
$1.6M
NHLBI NIH HHS R01 HL087017
6 · The paper itself

Abstract

backgroundCell therapy holds the most promising for acute and chronic deleterious respiratory diseases. However, the safety and tolerance for lung disorders are controversy.

methodsWe undertook a systematic review and meta-analyses of all 23 clinical studies of cell therapy. The outcomes were odds ratio (OR), risk difference (RD), Peto OR, relative risk, and mean difference of serious adverse events.

results342 systemic infusions and 57 bronchial instillations (204 recipients) of cells were analyzed for acute respiratory distress syndrome (ARDS), bronchopulmonary dysplasia, pulmonary arterial hypertension, silicosis, sarcoidosis, extensively drug-resistant tuberculosis, chronic obstructive pulmonary diseases (COPD), and idiopathic pulmonary fibrosis. The frequency of death in adults from any causes was 71 and 177 per 1,000 for cell therapy and controls, respectively, with an OR of 0.31 (95% CI: 0.03, 3.76) and RD of -0.22 (95% CI: -0.53, 0.09). No significant difference was found for ARDS and COPD. The frequency of deaths and non-fatal serious adverse events of 17 open studies were similar to those of randomized controlled trials. Moreover, serious adverse events of allogenic cells were greater than autologous preparations, as shown by frequency, OR and RD.

conclusionsWe conclude that either infusion or instillation of mesenchymal stem stromal or progenitor cells are well tolerated without serious adverse events causally related to cell treatment. Cell therapy has not been associated with significant changes in spirometry, immune function, cardiovascular activity, and the quality of life.

Indexed as

Cell- and Tissue-Based TherapyClinical Trials as TopicHumansMesenchymal Stem CellsOdds RatioRespiratory Tract DiseasesTreatment Outcomecell therapymeta-analysisrespiratory diseasesserious adverse eventssystematic review

Identifiers

PMID28430622
PMCPMC5444761
OpenAlexW2589829683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.